NCT07220525 Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
| NCT ID | NCT07220525 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Obstructive Sleep Apnea |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-15 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-12-15 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Whereas the available evidence mostly supports chronic sleep disruption as a risk factor for incident AF, less is known about the near-term risk of a discrete atrial fibrillation (AF) episode following a night of disrupted or poor-quality sleep. This prospective, randomized, case-crossover study aims to examine the acute effects of sleep disruption on clinically relevant cardiac ectopy pertinent to AF.
Eligibility Criteria
Inclusion Criteria: * Are age 21 years or older * Have a HGNS device implanted for obstructive sleep apnea and followed up at UCSF Health * Are willing to abstain from using the upper airway stimulation device for no more than two consecutive days as instructed over the 14-day trial period * Able and willing to provide written informed consent Exclusion Criteria: * Currently pregnant or trying to get pregnant * Are currently taking class 1 or 3 anti-arrhythmic medications * Have a history of permanent AF or expected to have continuous AF throughout the study period * Have congenital heart disease * Ventricular pacing \>40% * Are unable to read or sign to provide informed consent
Contact & Investigator
Gregory Marcus, MD, MAS
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07220525 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Obstructive Sleep Apnea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07220525 currently recruiting?
Yes, NCT07220525 is actively recruiting participants. Contact the research team at hannah.oo@ucsf.edu for enrollment information.
Where is the NCT07220525 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07220525 clinical trial?
NCT07220525 is sponsored by University of California, San Francisco. The principal investigator is Gregory Marcus, MD, MAS at University of California, San Francisco. The trial plans to enroll 100 participants.